| 21/58 | US=85 / Biol/Mol Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 242-9. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. CDKS; G1; FARMACOLOGICA CDK2 INIBIDOR; G1 PRISAO; PARADA DO CICLO CELULAR; SUPRESSOR DE TUMOR P53; APOPTOSE |
| 22/58 | US=85 / Biol/Mol Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 242-9. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. CDKS; FARMACOLOGICA CDK2 INIBIDOR; SUPRESSOR DE TUMOR P53; APOPTOSE; PRIVACAO DE SORO; PARADA DO CICLO CELULAR |
| 23/58 | US=85 / Biol/Mol Thomadaki H, Floros KV, Scorilas A. Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new menber BCL2L12. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 276-83. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. LEUCEMIA PROMIELOCITICA AGUDA; APOPTOSE; BAX; BCL2; BCL2L12; CASPASE-3; CITOTOXICIDADE; LADDERING DNA; FAS; HL-60; INIBIDOR MITOTICO; MTT; PCR; TAXOL; VINCRISTINA |
| 24/58 | US=96 / Biol/Mol Bulun SE, Lin Z, Zhao H, Lu M, Amin S, Reierstad S, Chen D. Regulation of aromatase expression in breast cancer tissue. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 121-31. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0. BRCA-1; ARF; CREB; AROMATASE; CANCER DE MAMA; PROSTAGLANDINA E2; JUNHO QUINASE; P38 QUINASE; RECEPTOR DE ESTROGENIO-&*945;; INIBIDOR DA AROMATASE |
| 25/58 | US=96 / Biol/Mol Dunn BK, Ryan A. Phase 3 trials of aromatase inhibitors for breast cancer prevention. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 141-61. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0. PREVENCAO DO CANCER DE MAMA; INIBIDOR DA AROMATASE; MODULADOR SELETIVO DO RECEPTOR DE ESTROGENIO; TAMOXIFENO; CANCER DE MAMA CONTRALATERAL; ARIMIDEX; TAMOXIFENO SOZINHO OU EM COMBINACAO; SERM; TAM; AI; CLBC; ATAC |
| 26/58 | US=15 / Gastro Kim GP, Billadeau DD. GSK-3B inhibition in pancreatic cancer. In: Lowy AM, Leach SD, Philip PA. Pancreatic cancer. New York: Springer, 2008. p. 635-46. ISBN 978-0-387-69250-0. |
| 27/58 | US=47 / Câncer Yap TA, Molife LR, Bono JS. CDK inhibitors as anticancer agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 135-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DE CDK; AGENTES ANTICANCERIGENOS; CICLO CELULAR; CICLINA DEPENDENTE DE QUINASE; CICLINA; INIBIDOR; FLAVOPIRIDOL; UCN-01; E7070; SELICICLIB; BMS 387032; ZD 304709 |
| 28/58 | US=65 / Biol/Mol Puente XS, Ordóñez GR, López-Otín C. Protease genomics and the cancer degradome. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 3-15. ISBN 978-0-387-69056-8. GENOMICA DE PROTEASE; CANCER DEGRADOME; DEGRADOME HUMANO; PESQUISA; REPERTORIO INIBIDOR DA PROTEASE; DEGRADOMES MAMIFEROS |
| 29/58 | US=65 / Biol/Mol Fingleton B. MMP inhibitor clinical trials-the past, present, and future. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 759-85. ISBN 978-0-387-69056-8. |
| 30/58 | US=67 / Biol/Mol Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2 |
| 31/58 | US=67 / Biol/Mol Thiagalingam S, Faller DV. The cancer epigenome: cann it be targeted for therapy?. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 97-113. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; EPIGENOMA; METILACAO DO DNA; DNA METIL TRANSFERASE; HISTONA ACETILTRANSFERASE; HISTONA-DESACETILASE; CODIGO DE HISTONAS; CODIGO EPIGENOMICO ATIVA; CODIGO EPIGENOMICO SILENCIADO; INIBIDOR DE HISTONA-DESACETILASE; TERAPIA DO CANCER |
| 32/58 | US=67 / Biol/Mol Atieh DM, Vahdat LT. Targeted therapy for beast cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 309-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE MAMA; TERAPIA-ALVO; TRASTUZUMABE; HER-2; MICROARRAY; BEVACIZUMABE; VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; LAPATINIBE; ANTICORPOS MONOCLONAIS; INIBIDOR DA TIROSINA QUINASE |
| 33/58 | US=67 / Biol/Mol Kitzen JJEM, de Jonge MJA, Verweij J. How to define treatment sucess or failure if tumors do not shrink: consequences for trial design. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 657-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MARCADOR SUBSTITUTO; TECIDO SUBSTITUTO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DA FARNESIL TRANSFERASE; SELECAO DE PACIENTE; IMAGEM; PROJETO DESCONTINUACAO RANDOMIZADO; INDICE DE MODULACAO DO CRESCIMENTO; TAXA DE PROGRESSAO; TAXA LIVRE DE PROGRESSAO |
| 34/58 | US=69 / Câncer Jabbour E, Cortes J, Kantarjian H. Targeted therapy in chronic myeloid leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 87-99. ISBN 978-1-60327-423-4. TERAPIA-ALVO NA LEUCEMIA MIELOIDE CRONICA; LEUCEMIA MIELOIDE CRONICA; INIBIDOR DA TIROSINA QUINASE; RESISTENCIA; BCR-ABL |
| 35/58 | US=69 / Câncer Wedgwood A, Younes A. Targeted therapy in lymphoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 157-82. ISBN 978-1-60327-423-4. TERAPIA-ALVO NO LINFOMA; ANTICORPO; LINFOMA; ANTIGENO; RECEPTOR; INIBIDOR; QUINASE |
| 36/58 | US=58 / Câncer Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS |
| 37/58 | US=84-A / Biol/Mol Yasui H, Hideshima T, Anderson KC. Transformig growth factor-B in developing and advanced cancers: inhibition of TGF-B signaling in multiple myeloma and its bone marrow microenvironment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 219-27. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0. TGF-B; IL-6; VEGF; TGF-B RECEPTOR TIPO I; TBRI; MIELOMA MULTIPLO; MICROAMBIENTE DA MEDULA OSSEA; FATOR TRANSFORMADOR DE CRESCIMENTO; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DE QUINASE SD-208 |
| 38/58 | US=84-A / Biol/Mol Reiss M. Development of inhibitors of transforming growth factor-B signaling for therapy: targetin transforming growth factor-B in metastasis: in vitro and in vivo mechanisms. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 609-34. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0. FATOR TRANSFORMADOR DE CRESCIMENTO - B; ANGIOGENESE; CANCER; MOTILIDADE; RESPOSTA IMUNE; INVASAO; METASTASE; TGF-B DO TIPO I; INIBIDOR DA QUINASE DO RECEPTOR; CRESCIMENTO TUMORAL |
| 39/58 | US=84-A / Biol/Mol Ling LE, Singh J, Chuaqui CE, Boriack-Sjodin PA, Corbley MJ, Lepage DJ, Silverio EL, Sun L, Papadatos JL, Shan F, Pontz T, Kam Cheung H, Zhang X, Arduini RM, Mead JN, Newman MN, Bowes S, Josiah S, Lee WC. Development of inhibitors of transforming growth factor-B signaling for therapy: the use of virtual screening in ALK5 kinase inhibitor discovery and validation of orally active ALK5 kinase inhibitors in oncology. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 685-96. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0. VIRTUAL; FARMACOFORO; INIBIDOR DE CINASE; ALK5; TGF-B RECEPTOR TIPO I; CRISTALOGRAFIA DE RAIOS X; TGF-B |
| 40/58 | US=90 / Biol/Mol Eigenbrot C. EGFR signaling networks: structure-function of EGFR kinase domain and its inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 31-45. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. CRISTALOGRAFIA DE RAIOS X; INIBIDOR DE MOLECULA PEQUENA; ESCAPAR MUTACAO; ACTIVACAO DA CINASE; ALLOSTERY; L858R; T790M |